These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 3352756)
1. Effects of matrix-associated chemotherapy in combination with irradiation in vivo. Howes AE; Herman TS; Montoya VP; Luck EE; Brown DM NCI Monogr; 1988; (6):141-3. PubMed ID: 3352756 [TBL] [Abstract][Full Text] [Related]
2. Response of murine tumors to matrix-associated cisplatin intratumoral implants. Yu NY; Conley FK; Luck EE; Brown DM NCI Monogr; 1988; (6):137-40. PubMed ID: 3352755 [TBL] [Abstract][Full Text] [Related]
3. Influence of treatment sequence on efficacy of fluorouracil and cisplatin intratumoral drug delivery in vivo. Yu NY; Patawaran MB; Chen JY; Orenberg EK; Brown DM; Luck EE Cancer J Sci Am; 1995; 1(3):215-21. PubMed ID: 9166479 [TBL] [Abstract][Full Text] [Related]
4. Improvement of differential toxicity between tumor and normal tissues using intratumoral injection with or without a slow-drug-release matrix system. Begg AC; Bartelink H; Stewart FA; Brown DM; Luck EE NCI Monogr; 1988; (6):133-6. PubMed ID: 3352754 [TBL] [Abstract][Full Text] [Related]
5. Tumor radiosensitization by sustained intratumoral release of bromodeoxyuridine. Doiron A; Yapp DT; Olivares M; Zhu JX; Lehnert S Cancer Res; 1999 Aug; 59(15):3677-81. PubMed ID: 10446981 [TBL] [Abstract][Full Text] [Related]
6. In vivo response of murine RIF tumors to thermochemotherapy. Neilan BA; Henle KJ J Med; 1989; 20(1):107-12. PubMed ID: 2468731 [TBL] [Abstract][Full Text] [Related]
7. Schedule-dependent therapeutic gain from the combination of fractionated irradiation plus c-DDP and 5-FU or plus c-DDP and cyclophosphamide in C3H/Km mouse model systems. Kallman RF; Rapacchietta D; Zaghloul MS Int J Radiat Oncol Biol Phys; 1991 Feb; 20(2):227-32. PubMed ID: 1991683 [TBL] [Abstract][Full Text] [Related]
8. Responses of RIF tumors to heat and drugs: dependence on tumor size. Li DJ; Hahn GM Cancer Treat Rep; 1984 Sep; 68(9):1149-51. PubMed ID: 6206943 [TBL] [Abstract][Full Text] [Related]
9. The combined antitumour effect of a new 5-fluorouracil derivative, BOF-A2, and radiation in vivo. Murata R; Shibamoto Y; Miyauchi S; Hirohashi M; Takagi T; Sasai K; Oya N; Hiraoka M Br J Cancer Suppl; 1996 Jul; 27():S114-6. PubMed ID: 8763861 [TBL] [Abstract][Full Text] [Related]
10. Systemic inhibition of tumor growth by soluble Flk-1 gene therapy combined with cisplatin. Wang R; Zhang XW; Wang GQ; Chen XC; Tian L; Yang HS; Hu M; Peng F; Yang JL; He QM; Zhang W; Jiang Y; Deng HX; Wen YJ; Li J; Zhao X; Wei YQ Cancer Gene Ther; 2006 Oct; 13(10):940-7. PubMed ID: 16799469 [TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models. Schmid FA; Sirotnak FM; Otter GM; DeGraw JI Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784 [TBL] [Abstract][Full Text] [Related]
12. Tumor responses following multiple hyperthermia and X-ray treatments: role of thermotolerance at the cellular level. Meyer JL; Van Kersen I; Hahn GM Cancer Res; 1986 Nov; 46(11):5691-5. PubMed ID: 3756917 [TBL] [Abstract][Full Text] [Related]
13. Multiple drug chemotherapy combined with multiple fractions per day (MFD) radiotherapy in an experimental solid tumor model. Hopkins HA; Looney WB; Carter WH; Reto DC; Campbell ED In Vivo; 1994; 8(1):107-12. PubMed ID: 8054501 [TBL] [Abstract][Full Text] [Related]
14. Acute in vivo resistance in high-dose therapy. Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940 [TBL] [Abstract][Full Text] [Related]
15. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma. Yuan X; Tabassi K; Williams JA Radiat Oncol Investig; 1999; 7(4):218-30. PubMed ID: 10492162 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice. Papadopoulou MV; Ji M; Ji X; Bloomer WD; Hollingshead MG Cancer Chemother Pharmacol; 2002 Dec; 50(6):501-8. PubMed ID: 12451478 [TBL] [Abstract][Full Text] [Related]
17. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001. Cunningham C; Nemunaitis J Hum Gene Ther; 2001 Aug; 12(12):1594-6. PubMed ID: 11529249 [TBL] [Abstract][Full Text] [Related]
18. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth. Jorgensen TJ; Tian H; Joseph IB; Menon K; Frost D Cancer Chemother Pharmacol; 2007 May; 59(6):725-32. PubMed ID: 16967299 [TBL] [Abstract][Full Text] [Related]
19. Optimizing the factors which modify thermal enhancement of melphalan in a spontaneous murine tumor. Mohamed F; Stuart OA; Glehen O; Urano M; Sugarbaker PH Cancer Chemother Pharmacol; 2006 Dec; 58(6):719-24. PubMed ID: 16614851 [TBL] [Abstract][Full Text] [Related]
20. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Pederson LC; Buchsbaum DJ; Vickers SM; Kancharla SR; Mayo MS; Curiel DT; Stackhouse MA Cancer Res; 1997 Oct; 57(19):4325-32. PubMed ID: 9331094 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]